Biological and Immune Responses to Current Anti-SARS-CoV-2 mRNA Vaccines beyond Anti-Spike Antibody Production

Table 1

Effectiveness against the SARS-CoV-2 Omicron (1.1.529) variant after 2 to 4 vaccine doses^a.

Ref	Vaccine type	no. of doses	Time after last dose (weeks)
			2-4	5-9	10-14	15-19	≥25
[39]	BNT162b2	2	65.5%	48.7%	30.1%	15.4%	8.8%
[39]	BNT162b2	3	67.2%	55%	45.7%
[40]	BNT162b2	4	30%
[39]	mRNA-1273	2	75.1%	52.8%	35.6%	25.3%	14.9%
[39]	mRNA-1273	3	66.3%	64.4%

^aCumulative data as calculated on populations from either England or Israel (for the 4^th dose only).